在氧化压力依赖的大脑内皮屏障功能障碍中改变的铜运输与阿尔茨海默氏病相关
bioRxiv : the preprint server for biology
|September 11, 2024
概括
失调的铜运输蛋白,特别是CTR1,通过增加氧化应激和破坏血脑屏障 (BBB) 来促进阿尔茨海默病 (AD). 这项研究强调了铜在与阿尔茨海默病相关的内皮功能障碍中的作用.
科学领域:
- 神经科学是一个神经科学.
- 细胞生物学 细胞生物学
- 生物化学 生物化学
背景情况:
- 阿尔茨海默氏病 (AD) 与氧化应激和血脑屏障 (BBB) 的破坏有关,涉及β-粉样蛋白 (Aβ) 积累.
- 铜 (Cu) 失调与阿尔茨海默病有关,但其在大脑内皮屏障功能中的作用尚不清楚.
- 铜运输蛋白控制铜水平,但它们在与AD相关的BBB功能障碍中的具体参与需要阐明.
研究的目的:
- 在AD小鼠模型中研究铜运输蛋白的表达.
- 确定这些蛋白质在Aβ42诱导的大脑内皮壁障碍功能障碍中的作用.
- 探索铜,氧化应激和AD中的BBB完整性之间的机制.
主要方法:
- 在AD小鼠模型和Aβ42治疗的人类大脑微血管内皮细胞 (hBMECs) 中检查了铜运输蛋白表达 (CTR1,ATP7A,ATP7B).
- 在5xFAD AD小鼠模型中使用ICP-MS测量海马铜水平.
- 在hBMEC中评估了Aβ42诱导的活性氧物种 (ROS) 生产和屏障功能 (超体电阻),使用铜化剂和CTR1敲击.
主要成果:
- 在AD小鼠海马体和Aβ42处理的hBMEC中,CTR1 (铜进口者) 的调控升高,而ATP7A/ATP7B (铜出口者) 的调控降低.
- 在5xFAD AD小鼠模型中观察到海马铜水平升高.
- 在hBMECs中Aβ42诱导的ROS产生,内皮屏障功能障碍和VE-cadherin酸化被铜化或CTR1敲击减轻.
结论:
- 不调节的铜运输蛋白导致AD大脑中的细胞内铜积累.
- Aβ42通过CTR1-铜依赖途径促进ROS依赖的大脑内皮屏障功能障碍和VE-cadherin酸化.
- 铜运输蛋白在阿尔茨海默病中氧化压力介导的BBB完整性损失中发挥着关键作用.
更多相关视频
10:36In Vitro Assays to Assess Blood-brain Barrier Mesh-like Vessel Formation and Disruption
Published on: June 20, 2017
8.5K
07:22Assessment of Blood-brain Barrier Permeability by Intravenous Infusion of FITC-labeled Albumin in a Mouse Model of Neurodegenerative Disease
Published on: November 8, 2017
9.9K
相关概念视频
Alzheimer's Disease: Overview
452
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
452
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
The Blood-brain Barrier
47.0K
Overview
47.0K
